In a report released yesterday, Leah R. Cann from Brookline Capital Markets maintained a Buy rating on CTI BioPharma (CTIC – Research Report), with a price target of $12.00. The company’s shares closed last Friday at $5.75, close to its 52-week high of $6.23.
According to TipRanks.com, Cann is a 2-star analyst with an average return of 0.5% and a 41.2% success rate. Cann covers the Healthcare sector, focusing on stocks such as Crispr Therapeutics AG, Intellia Therapeutics, and Syros Pharmaceuticals.
Currently, the analyst consensus on CTI BioPharma is a Strong Buy with an average price target of $8.44, a 40.0% upside from current levels. In a report issued on May 27, Needham also reiterated a Buy rating on the stock with a $8.00 price target.
The company has a one-year high of $6.23 and a one-year low of $1.43. Currently, CTI BioPharma has an average volume of 3.95M.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
CTI BioPharma Corp. operates as a biopharmaceutical company, which focuses on the development, acquisition, and commercialization of novel targeted therapies for blood-related cancers. Its products include PIXUVRI, Pacritinib, Tosedostat and Opaxio. The company was founded by James A. Bianco, Jack W. Singer, and Louis A. Bianco in September 1991 and is headquartered in Seattle, WA.
Read More on CTIC:
- Kepler Capital Sticks to Their Hold Rating for SpareBank 1 Nord-Norge (SPXXF)
- SpareBank 1 Helgeland (HGDPF) Receives a Buy from Kepler Capital
- HII Christens National Security Cutter Calhoun (WMSL 759)
- Vera Therapeutics Reports Positive Interim Phase 2 Data Showing MAU868 Has Significant BK Antiviral Activity in Kidney Transplant Patients
- Biomea Fusion Presents Novel Preclinical Data at ADA 2022 Suggesting BMF-219’s Potential as an Oral, Long-Acting Treatment for Type 2 Diabetes